FR104

DRUG2 trials

Sponsors

OSE Immunotherapeutics, Nantes University Hospital

Conditions

Complication of TransplantKidney TransplantationRheumatoid Arthritis

Phase 1

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

CompletedNCT02800811

OSE ImmunotherapeuticsComplication of Transplant, Rheumatoid Arthritis

Start: 2015-04-30End: 2016-07-31Updated: 2016-07-21

Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT Study

CompletedNCT04837092

Nantes University HospitalKidney Transplantation

Start: 2021-06-28End: 2025-04-14Updated: 2026-01-15